Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Disease evolution and outcomes in familial AML with germline CEBPA mutations

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A small change makes a big difference in Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub regulating granulo-monocytic fates

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Differences in Cell Cycle Status Underlie Transcriptional Heterogeneity in the HSC Compartment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Kiran Tawana
  • Jun Wang
  • Aline Renneville
  • Csaba Bödör
  • Robert Hills
  • Chey Loveday
  • Aleksandar Savic
  • Frederik W Van Delft
  • Jennifer Treleaven
  • Panayiotis Georgiades
  • Elizabeth Uglow
  • Norio Asou
  • Naokuni Uike
  • Maruša Debeljak
  • Janez Jazbec
  • Philip Ancliff
  • Rosemary Gale
  • Xavier Thomas
  • Valerie Mialou
  • Konstanze Döhner
  • Lars Bullinger
  • Beatrice Mueller
  • Thomas Pabst
  • Matthias Stelljes
  • Brigitte Schlegelberger
  • Eva Wozniak
  • Sameena Iqbal
  • Jessica Okosun
  • Shamzah Araf
  • Anne-Katrine Frank
  • Felicia B Lauridsen
  • Bo Porse
  • Claus Nerlov
  • Carolyn Owen
  • Inderjeet Dokal
  • John Gribben
  • Matthew Smith
  • Claude Preudhomme
  • Claude Chelala
  • Jamie Cavenagh
  • Jude Fitzgibbon
Vis graf over relationer

To date, in-depth molecular investigation of familial leukemia has been limited by the rarity of recognized cases. This study comprehensively examines the genetic events initiating leukemia and details the clinical progression of disease across multiple families harboring germline CEBPA mutations. Clinical data were collected from 10 CEBPA-mutated families, representing 24 members with AML. Whole-exome (WES) and deep sequencing were performed to genetically profile tumors and define patterns of clonal evolution. Germline CEBPA mutations clustered within the N-terminal and were highly penetrant, with AML presenting at a median age of 24.5yrs (1.75-46yrs). In all diagnostic tumors tested (n=18), double CEBPA mutations (CEBPAdm) were detected, with acquired (somatic) mutations preferentially targeting the C-terminal. Somatic CEBPA mutations were found to be unstable throughout the disease course, with different mutations identified at disease recurrence. Deep sequencing of diagnostic and relapse paired samples confirmed that relapse-associated CEBPA mutations were absent at diagnosis, suggesting recurrence was triggered by novel, independent clones. Integrated WES and deep sequencing subsequently revealed an entirely new complement of mutations at relapse, verifying the presentation of a de novo leukemic episode. The cumulative incidence of relapse in familial AML was 56% at 10yrs (n=11) and 3 patients experienced ≥3 disease episodes over a period of 17-20yrs. Durable responses to secondary therapies were observed, with prolonged median survival post relapse (8yrs) and long term overall survival (10yr OS, 67%). Our data reveal that familial CEBPA-mutated AML exhibits a unique model of disease progression, associated with favorable long term outcomes.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind126
Udgave nummer10
Sider (fra-til)1214-1223
ISSN0006-4971
DOI
StatusUdgivet - 3 sep. 2015

ID: 45569303